
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
We showcase Actylis, what the company stands for and how we serve our broad-ranging customer base globally.






